Research graph
References from Barking up the right tree: Immune checkpoint signatures of human and dog cancers. Local targets link to admitted publications; unresolved targets remain external evidence.
2018 Nobel Prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade - A personal account
10.1016/j.gendis.2018.10.003 · 2018 · External reference
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
10.1200/jco.2017.75.6270 · 2018 · External reference
A decade of immune-checkpoint inhibitors in cancer therapy
10.1038/s41467-020-17670-y · 2020 · External reference
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
10.1016/j.ejca.2021.03.010 · 2021 · External reference
Hyperprogression under Immunotherapy
10.3390/ijms20112674 · 2019 · External reference
Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
2015 · External reference
Unresolved reference
External reference
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
10.1158/1078-0432.ccr-16-1741 · 2017 · External reference
Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion
10.1126/science.1203486 · 2011 · External reference
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression
10.1186/1471-2164-10-625 · 2009 · External reference
Breed-predispositions to cancer in pedigree dogs
10.1155/2013/941275 · 2013 · External reference
Hyperprogression Under Immune Checkpoint-Based Immunotherapy-Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model
10.3390/cancers12040804 · 2020 · External reference
Spontaneous and genetically engineered animal models; use in preclinical cancer drug development
10.1016/j.ejca.2003.11.031 · 2004 · External reference
The dog as a cancer model
10.1038/nbt0906-1065b · 2006 · External reference
Immunotherapy for Dogs: Running Behind Humans
10.3389/fimmu.2018.00133 · 2018 · External reference
Next generation of immune checkpoint therapy in cancer: new developments and challenges
10.1186/s13045-018-0582-8 · 2018 · External reference
A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma
10.1186/s12967-022-03520-6 · 2022 · External reference
Dissecting the Role of Immune Checkpoint Regulation Patterns in Tumor Microenvironment and Prognosis of Gastric Cancer
10.3389/fgene.2022.853648 · 2022 · External reference
Five-gene signature for the prediction of response to immune checkpoint inhibitors in patients with gastric and urothelial carcinomas
10.1016/j.prp.2022.154233 · 2023 · External reference
Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis
10.1186/s40425-019-0752-4 · 2019 · External reference
Pan-cancer analysis of whole genomes
10.1038/s41586-020-1969-6 · 2020 · External reference
MultiQC: summarize analysis results for multiple tools and samples in a single report
10.1093/bioinformatics/btw354 · 2016 · External reference
Near-optimal probabilistic RNA-seq quantification
10.1038/nbt.3519 · 2016 · External reference
Software for computing and annotating genomic ranges
10.1371/journal.pcbi.1003118 · 2013 · External reference
Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences
10.12688/f1000research.7563.1 · 2015 · External reference
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
10.1186/s13059-014-0550-8 · 2014 · External reference
10.1007/978-0-387-98141-3
10.1007/978-0-387-98141-3 · 2009 · External reference
Unresolved reference
2023 · External reference
SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment
10.4049/jimmunol.2000300 · 2021 · External reference
Gene expression markers of Tumor Infiltrating Leukocytes
10.1186/s40425-017-0215-8 · 2017 · External reference
Proteomics. Tissue-based map of the human proteome
10.1126/science.1260419 · 2015 · External reference
STRING 8--a global view on proteins and their functional interactions in 630 organisms
10.1093/nar/gkn760 · 2009 · External reference
Comparative High-Resolution Transcriptome Sequencing of Lymphoma Cell Lines and de novo Lymphomas Reveals Cell-Line-Specific Pathway Dysregulation
10.1038/s41598-018-23207-7 · 2018 · External reference
Canine CD4+ T‐cell lymphoma identified by flow cytometry exhibits a consistent histomorphology and gene expression profile
10.1111/vco.12460 · 2019 · External reference
Comparative Molecular Life History of Spontaneous Canine and Human Gliomas
2020 · External reference
Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma
10.1158/1541-7786.mcr-19-0221 · 2019 · External reference
Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization
10.1016/j.ajpath.2013.12.025 · 2014 · External reference
Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer
10.1371/journal.pgen.1007571 · 2018 · External reference
Whole-exome and whole-transcriptome sequencing of canine mammary gland tumors
10.1038/s41597-019-0149-8 · 2019 · External reference
Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma
10.1158/0008-5472.can-17-0576 · 2018 · External reference
Ultra-frequent HRAS p.Q61R somatic mutation in canine acanthomatous ameloblastoma reveals pathogenic similarities with human ameloblastoma
10.1111/vco.12487 · 2019 · External reference
Transcriptomic analysis by RNA sequencing characterises malignant progression of canine insulinoma from normal tissue to metastatic disease
10.1038/s41598-020-68507-z · 2020 · External reference
RNA-seq transcriptome analysis of formalin fixed, paraffin-embedded canine meningioma
10.1371/journal.pone.0187150 · 2017 · External reference
Molecular homology between canine spontaneous oral squamous cell carcinomas and human head-and-neck squamous cell carcinomas reveals disease drivers and therapeutic vulnerabilities
10.1016/j.neo.2020.10.003 · 2020 · External reference
Suitability of ultrasound-guided fine-needle aspiration biopsy for transcriptome sequencing of the canine prostate
10.1038/s41598-019-49271-1 · 2019 · External reference
Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival
10.1002/ijc.32785 · 2020 · External reference
Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
10.1080/2162402x.2016.1261779 · 2016 · External reference
Unresolved reference
External reference
4-1BB: A promising target for cancer immunotherapy
10.3389/fonc.2022.968360 · 2022 · External reference
Immunotherapy in Renal Cell Carcinoma: The Future Is Now
10.3390/ijms21072532 · 2020 · External reference
PD-1 expression by canine T cells and functional effects of PD-1 blockade
10.1111/vco.12294 · 2017 · External reference
Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice
10.2460/ajvr.74.5.771 · 2013 · External reference
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
10.1038/s41698-021-00147-6 · 2021 · External reference
Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model
10.3233/blc-180204 · 2019 · External reference
Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope
10.3390/vetsci8070120 · 2021 · External reference
FoxP3, CTLA-4, and IDO in Canine Melanocytic Tumors
10.1177/0300985820960131 · 2021 · External reference
Expression profile of immunoregulatory factors in canine tumors
10.1016/j.vetimm.2022.110505 · 2022 · External reference
Improving human cancer therapy through the evaluation of pet dogs
10.1038/s41568-020-0297-3 · 2020 · External reference
The NKG2A immune checkpoint - a new direction in cancer immunotherapy
10.1038/s41571-019-0182-8 · 2019 · External reference
NKG2A expression identifies a subset of human Vδ2 T cells exerting the highest antitumor effector functions
10.1016/j.celrep.2021.109871 · 2021 · External reference
Neuron-interacting satellite glial cells in human trigeminal ganglia have an APC phenotype
10.4049/jimmunol.0900890 · 2009 · External reference
Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma
10.1111/vco.12459 · 2019 · External reference
B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis
2013 · External reference
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
10.1016/j.cell.2018.10.014 · 2018 · External reference
Monalizumab: inhibiting the novel immune checkpoint NKG2A
10.1186/s40425-019-0761-3 · 2019 · External reference
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses
10.1158/2326-6066.cir-14-0211 · 2015 · External reference
The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer
10.3389/fimmu.2023.1201632 · 2023 · External reference
Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia
10.1158/1078-0432.ccr-08-0229 · 2008 · External reference
OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
10.2147/ott.s214211 · 2019 · External reference
A structural model of the immune checkpoint CD160-HVEM complex derived from HDX-mass spectrometry and molecular modeling
10.18632/oncotarget.26570 · 2019 · External reference
Cancer immunology. The “cancer immunogram”
10.1126/science.aaf2834 · 2016 · External reference
B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look
10.1016/j.ygyno.2014.03.553 · 2014 · External reference
B7-H4 overexpression in ovarian tumors
10.1016/j.ygyno.2005.08.060 · 2006 · External reference
B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer
10.1186/s12935-018-0597-9 · 2018 · External reference
Roles of immune inhibitory molecule B7-H4 in cervical cancer
10.3892/or.2017.5481 · 2017 · External reference
B7-h4 is highly expressed in ductal and lobular breast cancer
10.1158/1078-0432.ccr-04-1658 · 2005 · External reference
Unresolved reference
External reference
Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs
10.3390/cancers13040785 · 2021 · External reference
Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
10.1136/jitc-2019-000266 · 2020 · External reference
Pharmacological modulation of GITRL/GITR system: therapeutic perspectives
10.1111/j.1476-5381.2011.01753.x · 2012 · External reference
CD28, CTLA-4 and their ligands: who does what and to whom?
10.1046/j.1365-2567.2000.00121.x · 2000 · External reference
Visualizing the life of mRNA in T cells
10.1042/bst20170003 · 2017 · External reference
Trogocytosis in innate immunity to cancer is an intimate relationship with unexpected outcomes
10.1016/j.isci.2022.105110 · 2022 · External reference
Multi-Omic Analysis of Esophageal Adenocarcinoma Uncovers Candidate Therapeutic Targets and Cancer-Selective Posttranscriptional Regulation
10.1016/j.mcpro.2024.100764 · 2024 · External reference
